Alcresta Therapeutics, Inc.
6
3
3
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
17%
1 trials in Phase 3/4
100%
2 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure
Role: collaborator
A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB
Role: collaborator
A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
Role: collaborator
Evaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients
Role: collaborator
Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study
Role: lead
Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)
Role: lead
All 6 trials loaded